European GeneICE Patent Granted and CRT Trials ...

For immediate release: 07.00hrs 8 August 2007

                                  VALIRX PLC                                   

                                  ("ValiRx")                                   

             European GeneICE Patent Granted and CRT Trials Update             

ValiRx (AIM: VAL), the cancer therapeutics company, today announces that its
proprietary gene-silencing technology, GeneICE, has received patent approval by
the European Patent Office covering 23 European states*. This follows the
granting of a US patent in April 2007.

ValiRx holds the rights to GeneICE through its subsidiary, Cronos Therapeutics
Ltd ("Cronos"), which has an exclusive worldwide license agreement with
Imperial College Innovations.

GeneICE compounds have the potential to freeze the development and growth of
cancerous cells and also have potential major applications in inflammatory
disease and inherited genetic conditions. Cronos' partner, Cancer Research UK,
a prestigious research institute in Europe, is currently undertaking
pre-clinical trials on GeneICE through Cancer Research Technology Limited
("CRT").

Dr Satu Vainikka, CEO of ValiRx, commented:

"We are delighted to have received this European patent which makes the
technology securely protected in the world's major life science markets: the US
and Europe. We anticipate being able to update the market regarding the initial
results from CRT's pre-clinical trials on GeneICE in September."

                                  ---ENDS---                                   

Notes to Editors

* European countries include Austria, Belgium, Bulgaria, Switzerland, Cyprus,
Czech Republic, Germany, Denmark, Estonia, Spain, Finland, France, the United
Kingdom, Greece, Ireland, Italy, Luxembourg, Monaco, the Netherlands, Portugal,
Sweden, Slovakia and Turkey.

Information on ValiRx

ValiRx is a biopharmaceutical development company that is building a portfolio
of complementary cancer-related therapeutic and diagnostic technologies. It
currently holds stakes in Cronos and Morphogenesis Inc.:

  * Cronos holds licenses to two innovative and potentially market changing
    technologies, GeneICE and HyperGenomics, as well as having an extensive
    portfolio of pending and granted patents in the areas of gene regulation
    and epigenetic diagnostic technologies;
   
  * Morphogenesis Inc. is developing a portfolio of cell therapy products for
    the treatment of chronic disorders. Its most advanced product, being
    ImmuneFxâ„¢ for which it recently received a patent from the US patent
    office.
   
ValiRx is headquartered in London, England.

For further information, please visit www.valirx.com

Contact Details:

     ValiRx Plc          WH Ireland         GTH Communications    
                                                                  
   Satu Vainikka       David Youngman        Toby Hall / Jade     
                                                Mamarbachi        
                                                                  
[phone]   [phone]     [phone]   
                            2174